These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19126809)

  • 1. Primary androgen deprivation therapy in men with prostate cancer.
    Laufman L
    JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809
    [No Abstract]   [Full Text] [Related]  

  • 2. Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data.
    Trinh QD; Schrag D
    JAMA Intern Med; 2014 Sep; 174(9):1468-9. PubMed ID: 25023522
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer: is androgen-deprivation therapy chosen wisely?
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073003
    [No Abstract]   [Full Text] [Related]  

  • 4. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate cancer: Say no to ADT for localized disease.
    Payton S
    Nat Rev Urol; 2014 Sep; 11(9):487. PubMed ID: 25069734
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 8. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
    Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
    JAMA; 2008 Jul; 300(2):173-81. PubMed ID: 18612114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy in advanced prostate cancer.
    Forster TH; Stoffel F; Gasser TC
    Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
    Printz C
    Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer: Why statins are beneficial.
    Thoma C
    Nat Rev Urol; 2015 Jul; 12(7):360. PubMed ID: 26032545
    [No Abstract]   [Full Text] [Related]  

  • 13. [Basic and clinical characteristics of flutamide].
    Suzuki K; Nakazato H; Kurokawa K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716
    [No Abstract]   [Full Text] [Related]  

  • 14. Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma.
    Gibbs SJ; Plowman PN
    Clin Oncol (R Coll Radiol); 1996; 8(6):346-52. PubMed ID: 8973848
    [No Abstract]   [Full Text] [Related]  

  • 15. Progress in Understanding What Is Being Statin(ed) in Prostate Cancer.
    Ramos JD; Yu EY
    JAMA Oncol; 2015 Jul; 1(4):428-30. PubMed ID: 26181247
    [No Abstract]   [Full Text] [Related]  

  • 16. Failure to report financial disclosure information.
    Lu-Yao G; Albertsen P; Shih W; Yao SL
    JAMA; 2009 Jan; 301(1):35-6. PubMed ID: 19126808
    [No Abstract]   [Full Text] [Related]  

  • 17. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
    Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
    JAMA Intern Med; 2014 Sep; 174(9):1460-7. PubMed ID: 25023796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent androgen suppression. Too good to be true?
    Abrahamsson PA
    Scand J Urol Nephrol Suppl; 1999; 203():45-9. PubMed ID: 10636570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment].
    Zgliczyński S; Borówka A
    Endokrynol Pol; 2005; 56(3):223. PubMed ID: 16350713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.